Related Experiment Videos
Efficacy of Levocetirizine in Reducing Double-J Stent-Related Symptoms: A Double-Blind Pilot Randomized Controlled
Marc Elias1,2, Rami Halaby1,2, Anthony Mina1,2
1School of Medicine and Medical Sciences, Holy Spirit University of Kaslik (USEK), Jounieh, Lebanon, usek.edu.lb.
Purpose:
The aim of this study is to evaluate the safety and efficacy of levocetirizine in reducing ureteral stent-related symptoms.
Methods:
In this single-center randomized controlled trial, 85 patients requiring double-J stent placement, 3 patients were excluded and 82 were allocated to start preoperatively levocetirizine 5 mg daily (Group B n = 41) or placebo (Group A n = 41) from stent insertion until stone removal. Primary outcomes were assessed using the Ureteral Stent Symptom Questionnaire (USSQ) and visual analog scale (VAS) for pain. Secondary outcomes included macroscopic assessment of ureteral inflammation and stent calcification during ureteroscopy for stone removal within 20 days.
Results:
Out of 82 participants included, three patients were excluded before analysis due to loss to follow-up or hospitalized for UTI that mimics stent-related symptoms. 79 patients were considered for final analysis. Group B showed a statistically significant reduction in stent-related morbidity USSQ across all subgroups compared to the placebo group and a lower VAS pain score (p < 0.05). Macroscopic assessment during stent removal also demonstrated statistically significantly less ureteral inflammation in Group B (17.07%) vs. 82.93% in Group A (p < 0.005).
Conclusion:
This pilot study indicates that levocetirizine effectively reduces stent-related symptoms and maintains a good safety profile. These findings suggest that levocetirizine may be a well-tolerated adjunct therapy for managing stent discomfort. Trial registration: Clinical trial.gov.identifier: LBCTR2025075754.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
01:15Upper Respiratory Drugs: First and Second-Generation Antihistamines
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...